Spire Healthcare Group (LON:SPI) Price Target Raised to GBX 300

Spire Healthcare Group (LON:SPI) had its price target increased by Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a research note issued to investors on Wednesday, Marketbeat reports. They currently have a buy rating on the stock.

Separately, JPMorgan Chase & Co. reissued an overweight rating and set a GBX 295 ($3.67) price objective on shares of Spire Healthcare Group in a research report on Monday, February 26th.

Spire Healthcare Group Stock Down 0.8 %

Shares of Spire Healthcare Group stock opened at GBX 246 ($3.06) on Wednesday. The company has a current ratio of 0.69, a quick ratio of 0.74 and a debt-to-equity ratio of 170.37. The company’s fifty day simple moving average is GBX 237.75 and its two-hundred day simple moving average is GBX 229.11. The company has a market cap of £994.16 million, a P/E ratio of 3,514.29, a PEG ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a 12-month low of GBX 204 ($2.54) and a 12-month high of GBX 321.71 ($4.00).

Spire Healthcare Group Increases Dividend

The business also recently disclosed a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be given a dividend of GBX 2.10 ($0.03) per share. This is an increase from Spire Healthcare Group’s previous dividend of $0.50. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, May 23rd. Spire Healthcare Group’s payout ratio is presently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.